Clinical trial NCT06233266: Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg
Official title: A Bioequivalence Study of a Randomized, Open-label, Single Dose, Two-way Crossover Design With Two-period, Two-treatment and Two-sequence of Ticagrelor Tablets 90 mg Relative to Originator in Healthy Thai Volunteers Under Fasting Condition.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Healthy Subjects
Keywords: Bioequivalence Ticagrelor Tablets 90 mg
Lead sponsor: Bio-innova Co., Ltd
Sponsor class: INDUSTRY
First posted: 2024-01-31
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 7 days washout period between the doses.

Detailed description: Title A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Ticagrelor Tablets 90 mg relative to Originator Ticagrelor Tablets 90 mg in healthy Thai volunteers under fasting condition.

Objectives The primary objective is to assess the rate and extent of absorption of a generic formulation with that of a reference formulation when given as equal labeled dose. The secondary objective is to evaluate the safety after oral administration of both test and reference formulation in healthy Thai volunteers.

Study Design Randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 7 days washout period between the doses.

Sample Size 36 Healthy Human Thai subjects. Two extra subjects if available, may be checked-in on the day of check in of period-I to compensate for any dropout prior to dosing of period-I. These subjects will be dosed if there are dropouts prior to dosing in period-I. If there are no dropouts, these subjects will be checked-out without being dosed after completion of dosing in period-I.

Drug-Product Test-Product: Ticagrelor Tablets 90 mg Reference-product: BRILINTATM (Film-Coated Tablets) 90 mg Manufactured by: AstraZeneca AB, Sweden

Administration After an overnight fasting at clinical facility of at least 10 hours, each volunteer will receive a single dose of Ticagrelor Tablets 90 mg of either test or reference with 250 mL of drinking water. Each volunteer will be allowed to drink water as desire except 1 hour before and after drug administration. The formulation is given in a crossover fashion as per the randomization schedule. After the administration, the subject's oral cavity will be checked by using flashlight to confirm complete medication and fluid consumption by pharmacist.

Blood Schedule In each period, a total of 23 blood samples (approximately 7 mL each) will be collected pre-dose (0.000 hour) and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.333, 3.667, 4.000, 4.500, 5.000, 6.000, 8.000, 10.000, 14.000, 20.000, 24.000, 36.000 and 48.000 hours after study drug administration, respectively. The sample collection at 36.000 and 48.000 hours after dosing will be on ambulatory basis (i.e. on separate visit).

Sample Collection Blood samples will be collected through an indwelling catheter placed in a vein using disposable syringe or through fresh venipuncture with disposable syringes and needles. Approximately 7 mL blood sample will be withdrawn and transferred to sample collection pre-labeled tubes containing K3EDTA as anticoagulant at each sampling time point. After collection of blood samples from each subject at each time point, samples will be centrifuged at 4000 rpm for 5 minutes at 4±2°C. After centrifugation, the plasma samples will be aliquot into two pre-labeled cryovials for approximately 1 mL per each cryovial. Cryovials containing plasma sample will be stored at -70±10 °C.

Analytical Method Ticagrelor and its active metabolite, AR-C124910XX plasma concentration will be assayed as per international Guidelines/In-house SOP by using a validated LC-MS/MS method

Pharmacokinetic Parameters Primary pharmacokinetic parameter: Cmax, AUC0→t and AUC0→∞ and secondary pharmacokinetic parameter: Tmax, T1/2, Kel, AUC0→t/AUC0→∞ will be determined from the plasma concentration data of analytes.

Statistical Analysis ANOVA, two one-sided tests for bioequivalence, for log-transformed pharmacokinetic parameters Cmax, AUC0→t and AUC0→∞ will be performed.

Acceptance Criteria for Bioequivalence To be considered as bioequivalent, the 90% CI of Cmax, AUC0→t and AUC0→∞ for the ratio of test to reference products for Ticagrelor should be in the interval of 80.00-125.00% for the log-transformed data.

Metabolite, AR-C124910XX will be provided as supportive data only.

Eligibility criteria: Inclusion Criteria:

1. Willingness to provide written informed consent prior to participate in the study.
2. Healthy Thai subjects are between 18 to 55 years of age.
3. The Body Mass Index (BMI) ranges from 18.5 to 30 kg/m2.
4. Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to draw 10 mL of blood for monitoring subjects' safety after the completion of the study.
5. Negative urine pregnancy test for women and no breast-feeding.
6. Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician.

Exclusion Criteria:

1. History or evidence of allergy or hypersensitivity to Ticagrelor or any related drugs or any of the excipients of this product.
2. Subject with B.P. is Systolic B.P \< 90, ≥140 mm/Hg, Diastolic B.P \< 60, ≥90 mm/Hg, pulse rate \> 100 beats per minute.
3. Serum bilirubin greater than 1.5 times the upper limit of reference range (ULRR).\*
4. Serum creatinine greater than 1.5 times the upper limit of reference range (ULRR).\*
5. Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2 times the upper limit of reference range (ULRR).\*
6. PT (Prothrombin time) and aPTT (Activated partial thromboplastin time) are above normal range.\*
7. Positive of hepatitis B or C virus.
8. Have more than one abnormal EKG, which is considered as clinically significant.\*
9. History or evidence of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope.
10. History or evidence of heart, renal, hepatic disease, pulmonary obstructive disease, bronchial asthma, hypertension or glaucoma.
11. History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy.
12. Any major illness in the past 3 months or any significant ongoing chronic medical illness.
13. History of psychiatric disorder.
14. History or presence of major active bleeding or abnormal bleeding due to hemorrhoids, epistaxis, gastrointestinal ulcer or other symptoms in past 1 month before the study drug administration and until the completion of the study.
15. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
16. History of usually smoking (more than 10 cigarettes per day within past 1 year), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of the study.
17. High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
18. History of grapefruit, pomelo or grapefruit products consumption and cannot stop at least 7 days before the study drug administration and until the completion of the study.
19. Positive drug abused test in urine (Benzodiazepines, Marijuana (THC), Methamphetamine, Cocaine and Opioids).
20. Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of contraception within 28 days (Depo-Provera must be discontinued at least 6 months) prior to receiving the first dose of study medication or Inducer/inhibitor CYP enzymes within 28 days prior to receiving the first dose of study medicine.
21. History of difficulty in accessibility of veins in left and right arm.
22. Blood donation (one unit or 450 mL) within the past 3 months before the study.
23. Participation in any clinical study within the past 3 months before the study.
24. Subjects who are unwilling or unable to comply with the lifestyle guidelines described in this protocol.

(\* Depend on decision of principal investigator and/or clinical investigator)

Primary outcomes:
measure: Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t)
timeFrame: Blood samples will be coll pre-dose and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.333, 3.667, 4.000, 4.500, 5.000, 6.000, 8.000, 10.000, 14.000, 20.000, 24.000, 36.000 and 48.000 hours after study drug administration
measure: Maximal measured plasma concentration (Cmax)
timeFrame: Blood samples will be coll pre-dose and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.333, 3.667, 4.000, 4.500, 5.000, 6.000, 8.000, 10.000, 14.000, 20.000, 24.000, 36.000 and 48.000 hours after study drug administration
Secondary outcomes:
measure: Number of subjects with adverse events
timeFrame: Approximately the day 14 after the last visit
Other outcomes:
Locations:
Study officials:
References: